KAT2B and non-small cell lung carcinoma: Low expression of KAT2B concurrent with a higher frequency of somatic genes mutation was associated with lower response efficacy to ICIs in NSCLC patients, while KAT2B was linked to IFN-γ regulation, antigen processing, and presentation (63).